<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489527</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-16685</org_study_id>
    <secondary_id>IISP ID 39582</secondary_id>
    <nct_id>NCT01489527</nct_id>
  </id_info>
  <brief_title>Preparedness Study - HPV Vaccine</brief_title>
  <official_title>Preparedness Study: Efficacy of HPV Vaccine to Reduce HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moffitt Cancer Center is the Coordinating Center for this study.

      The purpose of this study is to develop and test the infrastructure to conduct a future Phase
      III vaccine efficacy trial to assess trial feasibility, and to assess human papillomavirus
      (HPV) genotype distribution, data needed to design a Phase III trial. The investigators
      propose to conduct a Preparedness study among women ages 16-24 years of age residing in a
      region of South Africa with a high human immunodeficiency (HIV) incidence and prevalence.

      The specific aims of this study are to:

        1. Identify, recruit, enroll, and randomize a cohort of HIV negative women (200 per arm,
           400 total) ages 16-24 years to an HPV vaccine against 4 types (HPV 6, 11, 16, 18
           [Gardasil]) or placebo vaccine.

        2. Determine the cervical HPV prevalence and type distribution at enrollment, and cervical
           lesion prevalence among young females ages 16-24 years at high risk for HIV infection.

        3. Assess the rate of compliance through the 3-dose vaccination series
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study vaccine will be blindly administered as supplied on Day 1, Month 2, and Month 6.
      Both HPV and placebo vaccines will be in identical bottles, and all treatment codes will be
      kept under lock and key. All vaccines will be injected intramuscularly into the deltoid
      muscle by a member of the clinical staff. Each participant will be monitored for systemic and
      local reactions for 30 minutes postvaccination after each study vaccination for any adverse
      effects, including allergic reactions. Vaccine adverse events will continue to be monitored
      throughout the duration of the study period. Vaccine will be shipped to a central pharmacy at
      Stellenbosch University and stored in a refrigerator monitored and maintained at 2-8 C prior
      to distribution and local storage at participating clinical centers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Human Papillomavirus (HPV) Rate</measure>
    <time_frame>At Enrollment - 5 Month Enrollment Period</time_frame>
    <description>HPV type distribution and prevalence of each HPV type at enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Compliance Rate</measure>
    <time_frame>18 Months</time_frame>
    <description>Percentage of participants to complete the 3-dose vaccination series and all 4 study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Seropositive by HPV Type</measure>
    <time_frame>At Enrollment - 5 Month Enrollment Period</time_frame>
    <description>Percentage of participants who were seropositive to HPV at enrollment, by specific HPV type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Seroconverted to HPV Types 6, 11, 16, or 18</measure>
    <time_frame>18 Months</time_frame>
    <description>Percentage of participants who seroconverted to HPV types 6, 11, 16, or 18, following receipt of 3 doses of qHPV vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Seroconverted to HPV Types 31, 33, 45, or 58</measure>
    <time_frame>18 Months</time_frame>
    <description>The percent of women that seroconverted among those receiving qHPV vaccine compared to placebo vaccine recipients for HPV types 31, 33, 45, and 58, HPV types not directly targeted by the qHPV vaccine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Sexual Transmission of Infection</condition>
  <arm_group>
    <arm_group_label>Gardasil Vaccine Administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil Vaccine</intervention_name>
    <description>The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.</description>
    <arm_group_label>Gardasil Vaccine Administration</arm_group_label>
    <other_name>Gardasil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.</description>
    <arm_group_label>Placebo Administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ages 16-24 years of age residing in a region of South Africa with a high HIV
             incidence and prevalence

          -  HIV negative

          -  has ever had vaginal intercourse

          -  has never had Papanicolaou smear (Pap) testing or has only had normal Pap test results

          -  fully understands study procedures, risks involved in the study, and voluntarily
             agrees to participate by giving written informed consent

          -  agrees to refrain from douching/vaginal cleansing and using vaginal medications or
             preparations for 2 calendar days prior to the Day 1 visit as well as other future
             visits that include collection of cervical specimens

          -  agrees to refrain from sexual intercourse for 2 calendar days prior to the Day 1 visit
             as well as other future visits that include collection of cervical specimens

          -  agrees to utilize effective contraception during sexual intercourse (excluding the
             rhythm method, withdrawal alone, and emergency contraception) during the vaccination
             period.

          -  Informed consent procedures for females &lt;18 years of age: Informed consent and
             informed assent will be obtained from parents/legal guardians and adolescents
             respectively, prior to participation. The consent form will include information about
             the study and individual request for consent of participants to participate in the
             study. It will be emphasized that participation is voluntary and that participants are
             free to withdraw from the study at any stage without any disadvantage to them. An
             assessment of understanding will be conducted at screening to ensure that consent is
             informed.

        Exclusion Criteria:

          -  have a history of severe allergic reaction

          -  have a known allergy to any vaccine component (e.g., aluminum, yeast, or BENZONASE)

          -  are currently immuno-compromised

          -  have received a marketed HPV vaccine, or are pregnant and lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Giuliano, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stellenbosch University</name>
      <address>
        <city>Parow</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <results_first_submitted>January 5, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2015</results_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Placebo</keyword>
  <keyword>sexually transmitted infection (STI)</keyword>
  <keyword>HIV</keyword>
  <keyword>Human Immunodeficiency</keyword>
  <keyword>Gardasil</keyword>
  <keyword>HPV</keyword>
  <keyword>human papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Women residing in the Western Cape, South Africa were enrolled from November 2012 to July 2013 in a preparedness study. Participants were recruited from the Kraaifontein day hospital and the Bloekombos primary health care clinic by community workers and through word of mouth, flyers, and brochures.</recruitment_details>
      <pre_assignment_details>4 of the 406 participants randomized had a false HIV negative test result, reducing the participants to 202 in the Gardasil Arm and 200 in the Placebo Arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gardasil Vaccine Administration</title>
          <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Administration</title>
          <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="175"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not compliant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated participants</population>
      <group_list>
        <group group_id="B1">
          <title>Gardasil Vaccine Administration</title>
          <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Administration</title>
          <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="B2" value="20" lower_limit="16" upper_limit="24"/>
                    <measurement group_id="B3" value="20" lower_limit="16" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Human Papillomavirus (HPV) Rate</title>
        <description>HPV type distribution and prevalence of each HPV type at enrollment.</description>
        <time_frame>At Enrollment - 5 Month Enrollment Period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine Administration</title>
            <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Administration</title>
            <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Papillomavirus (HPV) Rate</title>
          <description>HPV type distribution and prevalence of each HPV type at enrollment.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any HPV Type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any High-Risk Type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Low-Risk Type</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Compliance Rate</title>
        <description>Percentage of participants to complete the 3-dose vaccination series and all 4 study visits.</description>
        <time_frame>18 Months</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine Administration</title>
            <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Administration</title>
            <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Compliance Rate</title>
          <description>Percentage of participants to complete the 3-dose vaccination series and all 4 study visits.</description>
          <population>All treated participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Seropositive by HPV Type</title>
        <description>Percentage of participants who were seropositive to HPV at enrollment, by specific HPV type.</description>
        <time_frame>At Enrollment - 5 Month Enrollment Period</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine Administration</title>
            <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Administration</title>
            <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Seropositive by HPV Type</title>
          <description>Percentage of participants who were seropositive to HPV at enrollment, by specific HPV type.</description>
          <population>All treated participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Seroconverted to HPV Types 6, 11, 16, or 18</title>
        <description>Percentage of participants who seroconverted to HPV types 6, 11, 16, or 18, following receipt of 3 doses of qHPV vaccine.</description>
        <time_frame>18 Months</time_frame>
        <population>Participants who were randomized to Gardasil and received all 3 doses of Gardasil</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine Administration</title>
            <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Administration</title>
            <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Seroconverted to HPV Types 6, 11, 16, or 18</title>
          <description>Percentage of participants who seroconverted to HPV types 6, 11, 16, or 18, following receipt of 3 doses of qHPV vaccine.</description>
          <population>Participants who were randomized to Gardasil and received all 3 doses of Gardasil</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Seroconverted to HPV Types 31, 33, 45, or 58</title>
        <description>The percent of women that seroconverted among those receiving qHPV vaccine compared to placebo vaccine recipients for HPV types 31, 33, 45, and 58, HPV types not directly targeted by the qHPV vaccine.</description>
        <time_frame>18 Months</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Gardasil Vaccine Administration</title>
            <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Administration</title>
            <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Seroconverted to HPV Types 31, 33, 45, or 58</title>
          <description>The percent of women that seroconverted among those receiving qHPV vaccine compared to placebo vaccine recipients for HPV types 31, 33, 45, and 58, HPV types not directly targeted by the qHPV vaccine.</description>
          <population>All treated participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gardasil Vaccine Administration</title>
          <description>Gardasil Vaccine injected intramuscularly into the deltoid or thigh muscle.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Administration</title>
          <description>Placebo injected intramuscularly into the deltoid or thigh muscle.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Anal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Immune system disorders - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="202"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vulval infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Irregular menstruation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Reproductive system and breast disorders - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The EVRI Trial had a short duration with limited follow-up time; therefore, clinical efficacy in reducing HIV acquisition cannot be assessed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anna R. Giuliano, Ph.D.</name_or_title>
      <organization>H. Lee Moffitt Cancer Center and Research Institute</organization>
      <phone>813-745-6820</phone>
      <email>anna.giuliano@moffitt.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

